| Literature DB >> 35883502 |
Mingjun Si1, Danyang Li1, Ting Liu1, Yuanyan Cai1, Jingyu Yang1, Lili Jiang2, Haitao Yu1,3.
Abstract
Fewer biomarkers can be used to predict systemic lupus erythematosus (SLE) related kidney injury. This paper presents an apriori algorithm of association rules to mine the predictive biomarkers for SLE-related kidney injury of negative proteinuria. An apriori algorithm of association rules was employed to identify biomarkers, and logistic regression analysis and spearman correlation analysis were used to evaluate the correlation between triglycerides and SLE-related kidney injury of negative proteinuria. Triglycerides were mined out by the apriori algorithm of association rules. The level of triglycerides was significantly higher, and it was an independent risk factor for SLE-related kidney injury. In the high-triglycerides group, the number of patients with SLE-related kidney injury, SLEDAI-2K, urine P-CAST, the level of blood urea nitrogen, serum creatinine, and proteinuria were increased. Triglycerides level was positively correlated with proteinuria and P-CAST and negatively correlated with albumin and IgG. The area under the ROC curve of triglycerides and triglycerides combined proteinuria was 0.72 and 0.82, respectively. Significantly, 50% of SLE-related kidney injuries of negative proteinuria could be identified by high triglycerides levels. High triglycerides level was found at the time of onset of kidney injury, and it was opposite to glomerular filtration rate. Triglycerides may be a potential marker for predicting SLE-related kidney injury, especially in SLE-related kidney injury of negative proteinuria. Triglycerides combined proteinuria could predict SLE-related kidney injury effectively.Entities:
Keywords: apriori algorithm; association rule mining; kidney injury; systemic lupus erythematosus; triglycerides
Mesh:
Substances:
Year: 2022 PMID: 35883502 PMCID: PMC9312825 DOI: 10.3390/biom12070945
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Flow diagram of the study enrolment process.
Demographics and clinical characteristics of SLE patients and healthy subjects.
| SLE Patients | Healthy Subjects | ||
|---|---|---|---|
| ( | ( | ||
|
| |||
| Age, years | 37.05 (24.74–49.36) | 36.72 (25.59–47.85) | 0.953 |
| Gender, n (%) | 1.000 | ||
| Male | 11 (6.96) | 11 (6.96) | |
| Female | 147 (93.04) | 147 (93.04) | |
| SLE damage index, score | 0.00 (0.00–1.00) | - | - |
| SLEDAI-2K, score | 7.00 (4.00–11.00) | - | - |
| BMI, kg/m2 | 21.09 (19.14–23.05) | - | - |
| Kidney injury, n (%) | 73 (46.20) | - | - |
| Renal biopsy class | 26 (35.62) | - | - |
| III/III + V | 4 (15.4) | - | - |
| IV/IV +V | 18 (69.2) | - | - |
| V only | 4 (15.4) | - | - |
| Creatinine > 108 μmol/L | 14 (19.18) | - | - |
| Proteinuria > 0.5 g/d | 55 (75.34) | - | - |
| Red blood cell > 5/HP | 50 (68.49) | - | - |
| P-CAST | 30 (41.09) | - | - |
|
| |||
| Triglycerides, mmol/L | 1.68 (1.20–2.44) | 1.08 (0.81–1.45) | <0.000 *** |
| HDL, mmol/L | 0.86 (0.65–1.11) | 1.31 (1.16–1.51) | <0.000 *** |
| LDL, mmol/L | 2.01 (1.58–2.75) | 2.40 (1.69–3.11) | 0.005 ** |
| Total cholesterol, mmol/L | 3.52 (2.88–4.66) | 4.58 (0.82–8.34) | <0.000 *** |
| AST/ALT | 1.53 (1.12–2.09) | 1.33 (1.14–1.65) | 0.003 ** |
| Hemoglobin, g/L | 108.50 (88.00–121.25) | 139.19 (125.68–142.7) | <0.000 *** |
| PDW, fl | 13.70 (12.20–16.20) | 16.75 (15.93–17.57) | <0.000 *** |
| Hematocrit, % | 32.03 (24.48–39.58) | 42.85 (39.09–46.61) | <0.000 *** |
| RDW-SD, fl | 47.50 (43.90–52.90) | 42.55 (39.96–45.14) | <0.000 *** |
| LYM, 109/L | 1.01 (0.68–1.46) | 1.93 (1.44–2.42) | <0.000 *** |
| BUN, mmol/L | 4.71 (3.51–6.83) | 4.54 (3.56–5.52) | 0.087 |
| Creatinine, μmol/L | 61.25 (51.00–77.28) | 57.20 (52.50–65.75) | 0.068 |
| Uric acid, μmol/L | 294.00 (236.00–381.25) | 304.75 (227.71–381.79) | 0.827 |
| LDH, U/L | 213.00 (173.00–314.75) | - | - |
| α-HBDH, U/L | 192.00 (150.00–273.00) | - | - |
| Proteinuria, g/d | 0.43 (0.14–1.81) | - | - |
| Albumin, g/L | 34.21 (26.71–41.71) | 46.40 (44.2–48.6) | <0.000 *** |
| P-CAST/μL | 0.39 (0.00–1.13) | - | - |
| Total protein, g/L | 67.14 (55.38–78.90) | 77.31 (72.58–82.04) | <0.000 *** |
| GFR, ml/min/1.73 m2 | 128.80 (76.23–181.37) | 138.45 (113.3–163.6) | 0.040 * |
SLE: systemic lupus erythematosus; SLEDAI-2K: systemic lupus erythematosus disease activity index 2000; BMI: body mass index; HDL: high density lipoprotein; LDL: low density lipoprotein; AST: aspartate transferase; ALT: alanine transferase; PDW: platelet distribution width; RDW-SD: red cell distribution width; LYM: absolute value of lymphocyte; BUN: blood urea nitrogen; LDH: lactic dehydrogenase; α-HBDH: α-hydroxybutyrate dehydrogenase; P-CAST: urine pathology cast; GFR: glomerular filtration rate. * p < 0.05, ** p < 0.01, *** p < 0.001.
The laboratory indicators of connecting to SLE-related kidney injury.
| Antecedent | Consequent | Lift | Support (%) | Confidence (%) |
|---|---|---|---|---|
| SLE-kidney dysfunction | Triglyceride | 1.462 | 46.203 | 71.233 |
| SLE-kidney dysfunction | LDH | 1.341 | 46.203 | 60.274 |
| SLE-kidney dysfunction | AST/ALT | 1.176 | 46.203 | 68.493 |
| SLE-kidney dysfunction | α-HBDH | 1.173 | 46.203 | 61.644 |
| SLE-kidney dysfunction | Total cholesterol | 1.169 | 46.203 | 73.973 |
| SLE-kidney dysfunction | Hemoglobin | 1.092 | 46.203 | 78.082 |
| SLE-kidney dysfunction | PDW | 1.036 | 46.203 | 61.644 |
| SLE-kidney dysfunction | Hematocrit | 1.024 | 46.203 | 84.932 |
| SLE-kidney dysfunction | RDW | 1.006 | 46.203 | 63.014 |
| SLE-kidney dysfunction | LYM | 1.003 | 46.203 | 78.082 |
LDH: lactic dehydrogenase; AST: aspartatetransferase; ALT: alanine transferase; α-HBDH: α-hydroxybutyrate dehydrogenase; PDW: platelet distribution width; RDW: red cell distribution width; LYM: absolute value of lymphocyte.
Univariate analysis of demographics and clinical characteristics associated with SLE-related kidney injury patients.
| SLE-Related Kidney Injury | SLE-No Kidney Injury | ||
|---|---|---|---|
| ( | ( | ||
|
| |||
| Age, years | 34.00 (25.00–41.50) | 39.00 (28.50–46.00) | 0.019 * |
| Gender (M/F) | 5/68 | 6/79 | 0.959 |
| Disease duration, months | 12.00 (1.40–36.00) | 7.00 (2.00–30.00) | 0.789 |
| BMI, kg/m2 | 21.09 (18.83–23.44) | 21.00 (19.36–22.88) | 0.936 |
|
| |||
| Triglycerides, mmol/L | 2.07 (1.58–3.19) | 1.42 (1.07–1.82) | <0.001 *** |
| HDL, mmol/L | 0.85 (0.60–1.11) | 0.88 (0.72–1.11) | 0.526 |
| LDL, mmol/L | 2.07 (1.45–2.89) | 2.12 (1.33–2.91) | 0.687 |
| LDH, U/L | 256.25 (187.95–350.48) | 196.45 (167.40–240.00) | 0.001 *** |
| AST/ALT | 1.71 (1.10–2.58) | 1.45 (1.13–1.85) | 0.093 |
| α-HBDH, U/L | 231.50 (156.00–316.75) | 183.00 (149.00–213.00) | 0.003 ** |
| Total cholesterol, mmol/L | 3.47 (2.82–5.26) | 3.53 (2.88–4.32) | 0.272 |
| Hemoglobin, g/L | 100.30 (74.09–126.51) | 110.06 (76.75–124.45) | 0.015 * |
| PDW, fl | 13.70 (11.60–16.05) | 13.65 (12.48–16.25) | 0.424 |
| Hematocrit, % | 29.95 (21.78–38.12) | 34.30 (29.45–37.25) | 0.001 *** |
| RDW-SD, fl | 47.50 (44.00–52.50) | 47.65 (43.83–53.45) | 0.938 |
| LYM, 109/L | 0.99 (0.61–1.44) | 1.05 (0.70–1.48) | 0.438 |
BMI: body mass index; HDL: high density lipoprotein; LDL: low density lipoprotein; LDH: lactic dehydrogenase; AST: aspartatetransferase; ALT: alanine transferase; α-HBDH: α-hydroxybutyrate dehydrogenase; PDW: platelet distribution width; RDW-SD: red cell distribution width-standard deviation; LYM: absolute value of lymphocyte; * p < 0.05, ** p < 0.01, *** p < 0.001.
Binary logistic regression analysis of risk factors associated with SLE-related kidney injury.
| Index | ORs (95% CIs) | |
|---|---|---|
| Triglycerides, mmol/L | 2.44 (1.48–4.03) | 0.001 ** |
| LDH, U/L | 1.01 (0.10–1.03) | 0.179 |
| α-HBDH, U/L | 0.99 (0.98–1.01) | 0.371 |
| Hemoglobin, g/L | 1.08 (0.99–1.18) | 0.074 |
| Hematocrit, % | 0.73 (0.54–1.00) | 0.050 |
| Age, years | 0.99 (0.95–1.02) | 0.410 |
| Gender, male/female | 0.48 (0.09–2.54) | 0.388 |
| BMI, kg/m2 | 1.02 (0.89–1.16) | 0.828 |
LDH: lactic dehydrogenase; α-HBDH: α-hydroxybutyrate dehydrogenase; SLEDAI-2K: systemic lupus erythematosus disease activity Index 2000; BMI: body mass index; ** p < 0.01.
Baseline characteristics of SLE patients with low and high triglycerides.
| Low-Triglycerides ( | High-Triglycerides ( | ||
|---|---|---|---|
|
| |||
| Age, years | 39.10 (27.4–50.8) | 32.50 (24–45) | 0.028 * |
| Gender, male/female | 6/82 | 5/63 | 1.000 |
| SLEDAI-2K, score | 5.00 (3.25–9.00) | 9.00 (4.00–14.00) | <0.001 *** |
| Disease duration, months | 10.50 (2.00–36.00) | 7.75 (2.25–24.88) | 0.857 |
| BMI | 20.75 (19.23–23.18) | 21.31 (18.38–24.24) | 0.781 |
| Kidney injury, n (%) | 26 (29.55) | 47 (69.12) | <0.001 *** |
| Gallbladder disorders, n (%) | 19 (21.59) | 13 (19.12) | 0.704 |
| Cardiovascular diseases, n (%) | 16 (18.18) | 20 (29.41) | 0.099 |
| Hematologic disorders, n (%) | 15 (17.05) | 11 (16.18) | 0.885 |
| Liver injury, n (%) | 12 (13.64) | 8 (11.76) | 0.729 |
| Thyroid disorders, n (%) | 11 (12.50) | 9 (13.24) | 0.892 |
| Splenic disorders, n (%) | 7 (7.95) | 4 (5.88) | 0.852 |
| Neurological symptoms, n (%) | 3 (3.41) | 4 (5.88) | 0.726 |
|
| |||
| Blood urea nitrogen, mmol/L | 4.35 (3.36–5.49) | 5.66 (3.79–9.29) | 0.004 ** |
| Creatinine, μmol/L | 58.90 (51.00–66.15) | 65.35 (51.48–98.95) | 0.024 * |
| Anti-ds-DNA antibody (+), n (%) | 17 (19.32%) | 14 (20.59%) | 0.888 |
| Anti-sm antibody (+), n (%) | 26 (29.55%) | 23 (33.82%) | 0.396 |
| ESR, mm/h | 52.00 (18.75–86.00) | 43.00 (27.00–79.00) | 0.644 |
| Immunoglobulin G, g/L | 17.85 (13.90–25.13) | 14.90 (9.89–19.50) | 0.002 ** |
| Immunoglobulin A, g/L | 2.66 (2.01–3.70) | 3.01 (2.21–3.52) | 0.436 |
| Immunoglobulin M, g/L | 1.38 (0.96–2.03) | 1.24 (0.90–1.81) | 0.650 |
| Complement 3, g/L | 0.71 (0.40–0.96) | 0.50 (0.32–0.77) | 0.010 * |
| Complement 4, g/L | 0.14 (0.06–0.23) | 0.095 (0.06–0.17) | 0.168 |
| CRP, mg/L | 3.89 (3.27–13.05) | 3.34 (3.08–9.68) | 0.267 |
| Proteinuria, g/24 h | 0.25 (0.13–0.83) | 0.95 (0.30–3.14) | <0.001 *** |
| Albumin, g/L | 37.55 (31.63–42.05) | 31.37 (23.93–38.81) | <0.001 *** |
| P-CAST/μL | 0.25 (0.00–0.59) | 0.52 (0.12–2.29) | 0.001 ** |
| Total protein, g/L | 70.67 (60.5–80.84) | 62.21 (50.22–74.2) | <0.001 *** |
SLEDAI-2K: systemic lupus erythematosus disease activity index 2000; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: c-reactive protein; P-CAST: urine pathology cast; * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 2The correlations between triglycerides and indicators of SLE-related kidney injury, including urine protein (A), IgG (C), and P-CAST (D), were determined by Spearman correlation analysis in patients with SLE-related kidney injury. The correlation between triglycerides and albumin (B) was determined by Pearson correlation analysis. p < 0.05 was considered statistically significant. IgG: immunoglobulin G; P-CAST: urine pathology cast.
Figure 3ROC curve analysis of triglycerides, proteinuria, and the combination between triglycerides and proteinuria to predict SLE-related kidney injury from SLE-no kidney injury. ROC: receiver operating characteristic.
The relationship between triglycerides and proteinuria in SLE-related kidney injury patients.
| Proteinuria (+), | Proteinuria (−), | Total | |
|---|---|---|---|
| High triglycerides, n | 37 | 8 | 45 |
| Low triglycerides, n | 17 | 8 | 25 |
| Total | 54 | 16 | 70 |
Figure 4SLE patients with different levels of serum triglycerides experience different outcomes. Patients showed higher levels of triglycerides when they developed renal involvement (A). One patient with a persistent decreasing trend of triglycerides levels had sustained amelioration of kidney function (B). eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease.